₹98.35
2.91%
Compare
Indo US Bio-Tech vs UPLIndo US Bio-Tech vs CoromandelIndo US Bio-Tech vs Kaveri Seed CompanyIndo US Bio-Tech vs Dhanuka AgritechIndo US Bio-Tech vs Madhya Bharat AgroIndo US Bio-Tech vs NIFTY 50 | MarketN

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 307.7M
Gross Profit 86.5M 28.10%
Operating Income 52.7M 17.13%
Net Income 47.0M 15.28%
EPS (Diluted) ₹2.35

Balance Sheet Metrics

Total Assets 978.4M
Total Liabilities 193.2M
Shareholders Equity 785.2M
Debt to Equity 0.25

Cash Flow Metrics

Revenue & Profitability Trend

Quarter Income Flow i

Annual Income Flow i

Indo US Bio-Tech Income Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Revenue i 1.0B 728.4M 617.4M 500.6M 401.1M
Cost of Goods Sold i 743.7M 493.7M 457.4M 368.3M 271.5M
Gross Profit i 294.7M 234.6M 160.0M 132.3M 129.6M
Gross Margin % i 28.4% 32.2% 25.9% 26.4% 32.3%
Operating Expenses
Research & Development i 60.7M 54.9M 17.2M 20.3M 20.8M
Selling, General & Administrative i 27.5M 20.1M 19.8M 16.3M 26.5M
Other Operating Expenses i 4.5M 115.0M 5.8M 17.6M 23.6M
Total Operating Expenses i 92.7M 190.0M 42.8M 54.2M 70.9M
Operating Income i 180.1M 99.8M 94.9M 66.6M 51.1M
Operating Margin % i 17.3% 13.7% 15.4% 13.3% 12.8%
Non-Operating Items
Interest Income i 696.6K 122.2K 0 25.6K 16.7K
Interest Expense i 14.4M 15.1M 11.2M 11.4M 11.2M
Other Non-Operating Income - - - - -
Pre-tax Income i 165.3M 87.9M 73.9M 53.1M 39.3M
Income Tax i 2.6M 5.5M 1.5M 2.5M -9.7M
Effective Tax Rate % i 1.6% 6.3% 2.0% 4.7% -24.7%
Net Income i 162.7M 82.4M 72.4M 50.6M 49.0M
Net Margin % i 15.7% 11.3% 11.7% 10.1% 12.2%
Key Metrics
EBITDA i 191.2M 111.0M 93.4M 71.7M 53.4M
EPS (Basic) i ₹8.12 ₹4.11 ₹7.51 ₹4.14 ₹3.36
EPS (Diluted) i ₹8.12 ₹4.11 ₹7.51 ₹4.14 ₹3.36
Basic Shares Outstanding i 20052000 20050122 9644612 12239274 14563176
Diluted Shares Outstanding i 20052000 20050122 9644612 12239274 14563176

Income Statement Trend

Join Our India Telegram Channel

Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!

Join Now →

Indo US Bio-Tech Balance Sheet From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Assets
Current Assets
Cash & Equivalents i 2.5M 492.2K 1.3M 481.8K 1.3M
Short-term Investments i - - - - -
Accounts Receivable i 150.0M 205.5M 247.1M 205.5M 247.1M
Inventory i 706.9M 233.6M 118.8M 233.6M 118.8M
Other Current Assets 381.0K 1.0K -1 469.0K -1
Total Current Assets i 867.3M 468.4M 381.3M 468.4M 381.3M
Non-Current Assets
Property, Plant & Equipment i 113.0K 55.5M 23.7M 55.5M 23.7M
Goodwill i - 0 0 0 0
Intangible Assets i - - - - -
Long-term Investments - - - - -
Other Non-Current Assets 1 -1 144.3K -1 144.3K
Total Non-Current Assets i 111.2M 87.8M 55.7M 87.8M 55.7M
Total Assets i 978.4M 556.2M 437.1M 556.2M 437.1M
Liabilities
Current Liabilities
Accounts Payable i 11.6M 28.2M 94.5M 27.0M 89.4M
Short-term Debt i 119.0M 91.1M 81.1M 91.1M 81.1M
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 10.7M 1 - 3.7M 16.4M
Total Current Liabilities i 163.4M 122.8M 180.9M 122.8M 180.9M
Non-Current Liabilities
Long-term Debt i 29.3M 37.3M 34.5M 37.3M 34.5M
Deferred Tax Liabilities i - 0 - 0 0
Other Non-Current Liabilities - 14.0M - 10.5M 7.9M
Total Non-Current Liabilities i 29.9M 48.2M 42.7M 48.2M 42.7M
Total Liabilities i 193.2M 171.1M 223.6M 171.1M 223.6M
Equity
Common Stock i 200.5M 91.7M 60.7M 91.7M 60.7M
Retained Earnings i 363.2M 147.4M 110.4M 147.4M 110.4M
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i 785.2M 385.1M 213.4M 385.1M 213.4M
Key Metrics
Total Debt i 148.4M 128.4M 115.7M 128.4M 115.7M
Working Capital i 703.9M 345.5M 200.4M 345.5M 200.4M

Balance Sheet Composition

Indo US Bio-Tech Cash Flow Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Operating Activities
Net Income i 165.3M 87.9M 73.9M 53.1M 39.3M
Depreciation & Amortization i - - - - -
Stock-Based Compensation i - - - - -
Working Capital Changes i -145.3M -115.1M -78.0M -71.2M -60.8M
Operating Cash Flow i 34.2M -12.1M 7.8M -6.3M -9.7M
Investing Activities
Capital Expenditures i -8.6M -26.1M -18.2M -39.7M -19.4M
Acquisitions i - - - - -
Investment Purchases i - - - - -
Investment Sales i - 0 99.0K - -
Investing Cash Flow i -8.6M -25.4M -16.9M -39.7M -19.4M
Financing Activities
Share Repurchases i - - - - -
Dividends Paid i -5.0M - - -1.5M -
Debt Issuance i 1.3M 11.0M - 2.8M 26.0M
Debt Repayment i - - -16.9M - -
Financing Cash Flow i 107.5K 27.3M 74.7M 38.3M 27.2M
Free Cash Flow i 5.6M -3.9M -13.0M -12.6M -18.0M
Net Change in Cash i 25.7M -10.2M 65.6M -7.6M -1.9M

Cash Flow Trend

Indo US Bio-Tech Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 14.45
Price to Book 2.48
Price to Sales 1.82
PEG Ratio -0.35

Profitability Ratios

Profit Margin 12.59%
Operating Margin 17.24%
Return on Equity 20.72%
Return on Assets 16.63%

Financial Health

Current Ratio 3.67
Debt to Equity 31.90
Beta -0.19

Per Share Data

EPS (TTM) ₹7.40
Book Value per Share ₹43.18
Revenue per Share ₹58.70

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
INDOUS 2.1B 14.45 2.48 20.72% 12.59% 31.90
UPL 620.3B 3.00 1.63 2.01% 0.09% 105.06
Coromandel 588.1B 24.57 4.83 18.41% 7.87% 11.60
Kaveri Seed Company 48.3B 16.04 2.69 18.71% 21.82% 0.00
Dhanuka Agritech 45.5B 6.46 2.95 21.17% 13.39% 2.06
Madhya Bharat Agro 44.4B 42.34 9.68 14.23% 5.92% 68.15
Nippun Rana

Nippun Rana

Chasing the market trend!

Hi, I’m Nippun, a tech enthusiast from Haryana, India. I have been coding since 2010 and using my coding skills in the share market since 2020. I have been coding scripts in Pinescript that work on Tradingview app/web. I love learning about new technology and applying it to solve real-world problems. Coding and share-market are my passions, and I enjoy finding and fixing bugs in code. I aim to share my skill set and experience that can positively impact society. Feel free to connect with me, an...

Financial data is updated regularly. All figures are in the company's reporting currency.